FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048001013> ?p ?o ?g. }

• W2048001013 endingPage "512" @default.
• W2048001013 startingPage "507" @default.
• W2048001013 abstract "No AccessJournal of UrologyAdult Urology1 Feb 2015The Impact of Bleomycin on Retroperitoneal Histology at Post-Chemotherapy Retroperitoneal Lymph Node Dissection of Good Risk Germ Cell Tumors K. Clint Cary, Jose A. Pedrosa, Hristos Z. Kaimakliotis, Timothy A. Masterson, Lawrence H. Einhorn, and Richard S. Foster K. Clint CaryK. Clint Cary More articles by this author , Jose A. PedrosaJose A. Pedrosa More articles by this author , Hristos Z. KaimakliotisHristos Z. Kaimakliotis More articles by this author , Timothy A. MastersonTimothy A. Masterson More articles by this author , Lawrence H. EinhornLawrence H. Einhorn More articles by this author , and Richard S. FosterRichard S. Foster More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.09.090AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Induction chemotherapy for International Germ Cell Cancer Collaborative Group (IGCCCG) good risk metastatic testicular cancer includes 3 cycles of bleomycin, etoposide and cisplatin (BEP x3) or 4 cycles of etoposide and cisplatin (EP x4). We examine differences in active cancer in the retroperitoneum between patients receiving BEP x3 compared to EP x4. Materials and Methods: The Indiana University Testis Cancer database was queried to identify IGCCCG good risk patients who received BEP x3 or EP x4 induction chemotherapy before retroperitoneal lymph node dissection. The primary outcome of interest was retroperitoneal histology. The association between the use of bleomycin in the induction regimen with active cancer in the retroperitoneal specimen was tested using a propensity score adjusted analysis. Results: A total of 179 men (79%) received BEP x3 while 47 (21%) received EP x4. Median age of the bleomycin, etoposide and cisplatin group was 27 years (range 15 to 50) vs 30 years (range 18 to 71) in the etoposide and cisplatin group. The incidence of active cancer in the retroperitoneal specimen at post-chemotherapy retroperitoneal lymph node dissection was significantly higher in the EP x4 group compared to the BEP x3 group (31.9% vs 7.8%, p <0.01). This significant difference in the bleomycin, etoposide and cisplatin vs etoposide and cisplatin groups remained in the propensity adjusted analysis (22.9% vs 7.8%, p=0.015). Conclusions: There was a higher incidence of active cancer in the retroperitoneal specimen in good risk patients who received 4 cycles of induction etoposide and cisplatin chemotherapy compared to 3 cycles of bleomycin, etoposide and cisplatin in this retrospective analysis. The overall burden of treatment may be higher for men receiving EP x4 for induction chemotherapy. References 1 : Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med1977; 87: 293. Google Scholar 2 : The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol1993; 11: 1300. Google Scholar 3 : Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol1995; 13: 470. Google Scholar 4 : Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol1997; 15: 1837. Google Scholar 5 : Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol2001; 19: 1629. Google Scholar 6 : Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol1989; 7: 387. Google Scholar 7 : Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol1993; 11: 598. Google Scholar 8 : International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol1997; 15: 594. Google Scholar 9 : Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc1984; 79: 516. Google Scholar 10 : Applied Logistic Regression. New York: Wiley & Sons2013. Google Scholar 11 : Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer1975; 36: 318. Google Scholar 12 : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med1987; 316: 1435. Google Scholar 13 : Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol2003; 14: 91. Google Scholar 14 : Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience. J Clin Oncol1998; 16: 702. Google Scholar 15 : Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol1997; 15: 2553. Google Scholar 16 : Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol2007; 18: 917. Google Scholar 17 : Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol1998; 16: 65. Google Scholar © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byde Wit R (2018) Optimal Management of Germ Cell Cancer: More a Matter of Expertise than of Chemotherapy RegimenJournal of Urology, VOL. 193, NO. 2, (391-393), Online publication date: 1-Feb-2015. Volume 193Issue 2February 2015Page: 507-512 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Keywordsbleomycinlymph node excisiontesticular neoplasmsMetricsAuthor Information K. Clint Cary More articles by this author Jose A. Pedrosa More articles by this author Hristos Z. Kaimakliotis More articles by this author Timothy A. Masterson More articles by this author Lawrence H. Einhorn More articles by this author Richard S. Foster More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2048001013 created "2016-06-24" @default.
• W2048001013 creator A5003811094 @default.
• W2048001013 creator A5014984711 @default.
• W2048001013 creator A5016474171 @default.
• W2048001013 creator A5035913183 @default.
• W2048001013 creator A5048660181 @default.
• W2048001013 creator A5071614462 @default.
• W2048001013 date "2015-02-01" @default.
• W2048001013 modified "2023-10-18" @default.
• W2048001013 title "The Impact of Bleomycin on Retroperitoneal Histology at Post-Chemotherapy Retroperitoneal Lymph Node Dissection of Good Risk Germ Cell Tumors" @default.
• W2048001013 cites W1770099949 @default.
• W2048001013 cites W1776213361 @default.
• W2048001013 cites W1804445123 @default.
• W2048001013 cites W1825421411 @default.
• W2048001013 cites W1849826284 @default.
• W2048001013 cites W1874463527 @default.
• W2048001013 cites W1961050161 @default.
• W2048001013 cites W2024320307 @default.
• W2048001013 cites W2060372099 @default.
• W2048001013 cites W2130244861 @default.
• W2048001013 cites W2149953171 @default.
• W2048001013 cites W2232684587 @default.
• W2048001013 cites W2323139555 @default.
• W2048001013 cites W4239728164 @default.
• W2048001013 cites W44254208 @default.
• W2048001013 doi "https://doi.org/10.1016/j.juro.2014.09.090" @default.
• W2048001013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25254937" @default.
• W2048001013 hasPublicationYear "2015" @default.
• W2048001013 type Work @default.
• W2048001013 sameAs 2048001013 @default.
• W2048001013 citedByCount "12" @default.
• W2048001013 countsByYear W20480010132015 @default.
• W2048001013 countsByYear W20480010132017 @default.
• W2048001013 countsByYear W20480010132018 @default.
• W2048001013 countsByYear W20480010132019 @default.
• W2048001013 countsByYear W20480010132020 @default.
• W2048001013 countsByYear W20480010132021 @default.
• W2048001013 countsByYear W20480010132022 @default.
• W2048001013 countsByYear W20480010132023 @default.
• W2048001013 crossrefType "journal-article" @default.
• W2048001013 hasAuthorship W2048001013A5003811094 @default.
• W2048001013 hasAuthorship W2048001013A5014984711 @default.
• W2048001013 hasAuthorship W2048001013A5016474171 @default.
• W2048001013 hasAuthorship W2048001013A5035913183 @default.
• W2048001013 hasAuthorship W2048001013A5048660181 @default.
• W2048001013 hasAuthorship W2048001013A5071614462 @default.
• W2048001013 hasConcept C126322002 @default.
• W2048001013 hasConcept C141071460 @default.
• W2048001013 hasConcept C143998085 @default.
• W2048001013 hasConcept C2775862295 @default.
• W2048001013 hasConcept C2776212926 @default.
• W2048001013 hasConcept C2776232574 @default.
• W2048001013 hasConcept C2776694085 @default.
• W2048001013 hasConcept C2776938808 @default.
• W2048001013 hasConcept C2778119113 @default.
• W2048001013 hasConcept C2778239845 @default.
• W2048001013 hasConcept C2779511695 @default.
• W2048001013 hasConcept C2780824555 @default.
• W2048001013 hasConcept C2780849966 @default.
• W2048001013 hasConcept C71924100 @default.
• W2048001013 hasConceptScore W2048001013C126322002 @default.
• W2048001013 hasConceptScore W2048001013C141071460 @default.
• W2048001013 hasConceptScore W2048001013C143998085 @default.
• W2048001013 hasConceptScore W2048001013C2775862295 @default.
• W2048001013 hasConceptScore W2048001013C2776212926 @default.
• W2048001013 hasConceptScore W2048001013C2776232574 @default.
• W2048001013 hasConceptScore W2048001013C2776694085 @default.
• W2048001013 hasConceptScore W2048001013C2776938808 @default.
• W2048001013 hasConceptScore W2048001013C2778119113 @default.
• W2048001013 hasConceptScore W2048001013C2778239845 @default.
• W2048001013 hasConceptScore W2048001013C2779511695 @default.
• W2048001013 hasConceptScore W2048001013C2780824555 @default.
• W2048001013 hasConceptScore W2048001013C2780849966 @default.
• W2048001013 hasConceptScore W2048001013C71924100 @default.
• W2048001013 hasIssue "2" @default.
• W2048001013 hasLocation W20480010131 @default.
• W2048001013 hasLocation W20480010132 @default.
• W2048001013 hasOpenAccess W2048001013 @default.
• W2048001013 hasPrimaryLocation W20480010131 @default.
• W2048001013 hasRelatedWork W2048001013 @default.
• W2048001013 hasRelatedWork W2065740365 @default.
• W2048001013 hasRelatedWork W2070070122 @default.
• W2048001013 hasRelatedWork W20929017 @default.
• W2048001013 hasRelatedWork W2095443166 @default.
• W2048001013 hasRelatedWork W2313146572 @default.
• W2048001013 hasRelatedWork W2402288882 @default.
• W2048001013 hasRelatedWork W2422080463 @default.
• W2048001013 hasRelatedWork W2424108965 @default.
• W2048001013 hasRelatedWork W2890181724 @default.
• W2048001013 hasVolume "193" @default.
• W2048001013 isParatext "false" @default.
• W2048001013 isRetracted "false" @default.
• W2048001013 magId "2048001013" @default.
• W2048001013 workType "article" @default.